Biggest News Aggregation in the World
📰 Briefing Document News

Page 3 - Briefing Document News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Briefing Document. Real-time updates on events, politics, business and more.

Y-MABS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or...
New York United States Josh Wilson Prnewswire Faruqi Y Mabs Therapeutics Inc Drug Administration

Y-MABS THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc.

/PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 20, 2023 to file lead plaintiff applications...
New York United States Prnewswire Claimsfiler Lawyers At Kahn Swick Foti Y Mabs Therapeutics Inc United States District Court

Y-MABS SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or...
New York United States Josh Wilson Prnewswire Faruqi Y Mabs Therapeutics Inc Drug Administration

Y-MABS SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or...
New York United States Josh Wilson Prnewswire Faruqi Y Mabs Therapeutics Inc Drug Administration

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Y-MABS THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc.

/PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 20, 2023 to file lead plaintiff applications...
New York United States Prnewswire Claimsfiler Lawyers At Kahn Swick Foti Y Mabs Therapeutics Inc United States District Court

Y-MABS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or...
New York United States Josh Wilson Prnewswire Faruqi Y Mabs Therapeutics Inc Drug Administration

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

/PRNewswire/ -- Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the...
New York United States Peter Allocco Advisory Committee Adcom Meeting Bernstein Liebhard Y Mabs Therapeutics Inc

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science